Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II trial of imetelstat in essential thrombocythemia requiring cytoreduction after failure/intolerance or refusal of standard therapy
2010-023076-10Phase 2Completed
- Sponsor
- Geron Corporation
- Start
- Dec 2010
- Modality
- Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of imetelstat in thrombocythemia, sponsored by Geron Corporation. Primary endpoint: Best overall hematologic response rate. Started Dec 2010; status: completed.
02
Drugs
imetelstat
03
Conditions
thrombocythemia
Beyond the preview
Go deeper on 2010-023076-10.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-023076-10.